When injection is the right starting point

For many patients with a focal knee cartilage defect, the answer to 'do I need surgery?' is no — at least not yet, and for a significant number, not at all. A ChondroFiller® collagen scaffold injection, placed under ultrasound guidance in a 30–45 minute outpatient appointment, is a clinically appropriate first-line treatment in its own right: no incision, no general anaesthetic, no hospital admission.

The decision logic here is not about avoiding surgery at all costs — it is about matching treatment intensity to clinical need. When MRI imaging supports a stand-alone injection, the clinical literature is explicit: proceeding directly to an operation at that point constitutes over-treatment. Defect size, location, and the full patient picture determine the right pathway, not surgical availability or convention.

The sections below work through the biology of why cartilage needs external support, what the published outcome data show for the injection pathway, and how clinicians identify which patients are best served by injection alone and which require surgical escalation.

What ChondroFiller is and how the scaffold works

ChondroFiller® is not a lubricant, and it is not a permanent filler. It is a CE-marked Class III medical device — a highly purified, acellular Type I collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany — and understanding its mechanism helps explain why it occupies a distinct category within the cartilage repair toolkit.

Articular cartilage has no blood supply. That single biological fact explains why a bruised muscle heals in days and a worn cartilage surface does not: there are no vessels to deliver the inflammatory cells and progenitor stem cells that initiate repair. What cartilage can do, given the right structural template, is recruit progenitor cells from the surrounding synovium and subchondral bone — if those cells have somewhere to anchor and organise.

That is what the scaffold provides. Delivered as an injectable gel under real-time ultrasound guidance, the collagen polymerises in situ once it contacts the joint environment, forming a physical layer over the worn articular surface. The patient's own progenitor cells migrate into this matrix and, over roughly six to twelve months, lay down new cartilage tissue — a process described as acellular matrix-induced chondrogenesis.

This is a top-down approach: the scaffold is placed over the defect from the articular surface inward. Surgical techniques such as microfracture or AMIC work from the bottom up, penetrating or exposing subchondral bone to provoke a repair response. The injection requires neither.

Hyaluronic acid acts primarily as a joint lubricant without providing a structural template for cell migration. Polyacrylamide hydrogels such as Arthrosamid® are permanent, non-biodegradable fillers that cushion the joint but do not recruit cells or support tissue formation. ChondroFiller promotes endogenous repair by giving the body's own migrating cells a scaffold to work within.

What the clinical outcomes show

Across four knee studies summarised in the manufacturer's 2025 Clinical Evaluation Report, IKDC scores improved by approximately 30 points on average over 12 months. That number matters in context: the minimum clinically important difference on the IKDC scale — the threshold below which a patient is unlikely to notice functional benefit — is 16.7 points. A 30-point gain is roughly double that threshold, translating in practical terms to meaningful reductions in pain on activity and a measurable return of joint function.

The strongest individual dataset comes from a prospective post-market clinical follow-up (PMCF) study by Jerosch et al., which recorded a mean IKDC improvement of 32.4 points sustained — and marginally increased — at three years, with patients reaching a final functional score of 80.

Structural MRI data add a complementary picture. MOCART scores in European studies ranged from 81.6 to 84.3 at 12 months, indicating greater than 80% defect filling and good integration with surrounding native cartilage. The progression from MOCART 65.3 at four weeks to 81.6 at one year confirms that repair tissue matures gradually rather than appearing immediately. Post-injection imaging also shows reduction in bone marrow oedema and diminished periarticular effusion — changes consistent with reduced joint inflammation.

These results should be read with appropriate caution. All published data derive from manufacturer-sponsored or single-centre European studies; no independent, head-to-head randomised controlled trial comparing the injection pathway against arthroscopic surgery has been published, and follow-up beyond three years remains limited. For a patient deciding now, the available three-year durability data offer a reasonable working horizon: current evidence suggests functional gains are maintained at that point, even if the trajectory beyond it is not yet established.

Who the injection pathway suits

Broadly, the injection pathway is open to a wider range of patients than many expect. There is no upper age limit, and the available clinical literature sets no ceiling on defect size for the injection route.

The most relevant variable is whether the cartilage damage is focal — confined to a specific area — rather than global. Kellgren-Lawrence grading is the standard radiological classification of osteoarthritis severity, running from Grade I (early changes) to Grade IV (severe narrowing). Even patients graded III or IV are not automatically excluded: what matters is whether the pattern of damage is patchy and structurally repairable rather than involving total destruction of the joint surface. Where the entire joint is compromised and mechanical alignment has been lost, joint replacement addresses the problem in a way an injection cannot — the scaffold needs viable surrounding tissue to work with.

MRI is the gating assessment. Cartilage-sensitive sequences that reveal partial or full-thickness focal loss — within a joint that is otherwise structurally intact — are the setting in which the injection has been studied and shown meaningful clinical benefit. At MSK Doctors, onMRI™ AI-assisted analysis can help the consulting clinician characterise defect depth and extent before a decision is reached.

The size and pattern of that focal damage also shapes the next question: whether the injection alone is sufficient, or whether it needs to be paired with a more involved procedure.

Injection vs surgery: how the decision is made

When a defect is too large or structurally complex for the injection pathway alone, the next step is the Liquid Cartilage™ protocol — a single arthroscopic procedure that pairs the ChondroFiller collagen scaffold with the patient's own mesenchymal stem cells (MSCs), harvested from bone marrow, fat, or platelet-rich fibrin and co-delivered under arthroscopic vision.

The surgical route is indicated where direct visualisation and mechanical debridement of the joint are clinically necessary — typically for unstable, localised Grade III or IV focal defects where the defect bed requires preparation that an outpatient injection cannot achieve. No single variable determines this boundary: Kellgren-Lawrence grade, defect dimensions, and age are each relevant, but it is the combination of imaging findings, symptom severity, and functional goals — assessed together at the point of consultation — that defines which step is clinically appropriate.

These two options are not competing products. The injection and the Liquid Cartilage™ procedure occupy different rungs of the same treatment hierarchy — the injection is the lower-complexity first step, and the arthroscopic protocol is the next step only if escalation is clinically justified. Cost is a secondary but real consideration: as guide costs, the injection pathway is substantially less expensive than the full arthroscopic route, though current pricing should be confirmed at the time of consultation.

The key reassurance for patients is that being offered the injection does not mean surgery is being deferred or withheld — it means surgery has been considered and found unnecessary at that stage of the clinical picture.

Getting assessed at MSK Doctors

Patients across Lincolnshire and the wider East Midlands can access a consultant-led knee cartilage assessment at MSK Doctors without a GP referral and without joining an NHS waiting list. The main assessment sites for non-London patients are Sleaford (NG34) — which houses the Open MRI scanner and the Regeneration Hub — and Grantham (NG31), home to the MFO Life Sciences Lab. The consulting team will review any existing imaging or arrange MRI as part of the assessment pathway to determine whether ChondroFiller injection, the Liquid Cartilage™ protocol, or another approach best fits the clinical picture. London-based patients can access the same assessment expertise through the London Cartilage Clinic, the group's London arm. To book a consultation without a referral, visit mskdoctors.com.

1. [1] Knee cartilage replacement therapy. https://en.wikipedia.org/?curid=4984243 https://en.wikipedia.org/?curid=4984243
2. [2] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351